FDA Seeks Injunction Against Endotec For Premarket Violations
This article was originally published in The Gray Sheet
Executive Summary
FDA announced Oct. 6 it has brought suit against orthopedic implant manufacturer Endotec seeking to permanently halt sales of the firm's total joint replacement devices
You may also be interested in...
Endotec To Countersue FDA In Response To Injunction Attempt
Endotec President Michael Pappas says his firm will countersue FDA in response to a federal lawsuit seeking a permanent injunction against the company
Endotec To Countersue FDA In Response To Injunction Attempt
Endotec President Michael Pappas says his firm will countersue FDA in response to a federal lawsuit seeking a permanent injunction against the company
Ankle Prosthetic Petition Opposed; Endotec Says AIP Corrective Actions OK’d
A long-pending FDL-1petition under FDA review to reclassify mobile-bearing total ankle replacement prostheses from Class III to Class II faces new opposition